Reduced Stimulant Use Is Not Treatment Failure

The clinical vignette below is a fictional composite created for education. It does not describe a real patient.

A patient enters outpatient treatment using methamphetamine on roughly 20 days each month. Twelve weeks later, the patient reports use on four days in the past month. There are fewer missed shifts, less craving, no recurrence of stimulant-associated paranoia, and better attendance. A urine test is still positive.

The assessment says: "Failed treatment."

That conclusion is too simple.

The positive test matters. So does the continuing risk. But neither erases the change in frequency, function, symptoms, or engagement. If the chart records only abstinent versus not abstinent, it may miss clinically meaningful progress. If it records the reduction as success without qualification, it may miss ongoing danger.

The useful question is not whether reduced use is good or bad. It is what reduced use means in this patient, after this treatment exposure, with these harms, and over this period of time.

A 2024 study in Addiction pooled data from 13 randomized medication trials involving 2,062 treatment-seeking adults with cocaine or methamphetamine use disorders. The investigators were not testing whether one medication worked better than another. They combined participants from intervention and control groups, adjusted for treatment assignment, and asked whether reduced frequency of use behaved like a clinically meaningful outcome.

Use during the past 30 days was divided into three levels: no use, use on one to four days, and use on five or more days. Reduced use meant moving from the highest-frequency group to one to four days. Abstinence required self-report plus negative urine toxicology during the final month.

More participants reduced their use than achieved abstinence: 18.0 percent versus 14.2 percent.

Reduced use was associated with improvement in several measures, including craving, drug-seeking behavior, depression severity, and psychosocial functioning. Those associations were generally weaker than the associations observed with abstinence. Reduced use was not associated with improvement on the study's HIV risk-behavior measure.

That makes reduced use informative. It does not make it sufficient.

This was a secondary analysis of trials originally designed to test medications. It was not a randomized comparison of reduced use against abstinence, and it cannot prove that reducing use caused every associated improvement.

The trials were short, most lasting about 12 weeks. Outcome data were missing for a substantial portion of the pooled sample. Measures from different trials had to be harmonized. Participants were treatment-seeking adults in controlled US research settings, which limits how confidently the findings can be generalized to other populations or routine care.

The authors also pooled intervention and control groups because their purpose was to examine the validity of the outcome. The analysis therefore cannot tell a psychiatrist that improvement in a particular patient was caused by a prescribed medication.

A published correction repaired the formatting of Table 2 and restored labels omitted from Figure 2. The corrected material supports the same bounded interpretation: reduced use was associated with several indicators of improvement, usually less strongly than abstinence. The correction did not announce a reversal of the study's principal conclusion.

Frequency of use is only one dimension of exposure.

Four days of use may be a profound improvement from 20 days. Four days of injection use with fentanyl exposure, chest pain, psychosis, or unsafe sexual behavior may still represent urgent risk. A patient may use on fewer days but consume more during each episode. Route, potency, contamination, co-use, sleep deprivation, and the setting of use can all change the clinical meaning of the same frequency.

That is why abstinence, progress, and safety are not synonyms.

For many patients, abstinence remains the safest and preferred goal. It may also be the patient's own goal. Recognizing reduced use does not require abandoning that aim.

It requires avoiding three errors.

The first is calling every nonabstinent outcome a failure. That can flatten a changing clinical course into a binary label and obscure which parts of the plan are helping.

The second is calling any reduction a success. Frequency can fall while dose per episode, route-related harm, co-use, psychiatric instability, cardiovascular risk, or overdose exposure worsens.

The third is crediting a medication merely because improvement occurred after it was prescribed. Timing is not causation. A prescription is not the same as adherence, adequate exposure, or evidence that the medication produced the observed change.

The ASAM/AAAP guideline recommends contingency management as a primary component of treatment for stimulant use disorder, with a high-certainty, strong recommendation. It also permits consideration of several medications off label in selected circumstances, often through conditional recommendations based on low- or moderate-certainty evidence. Those recommendations are not interchangeable, and some require specialist competency and close monitoring.

Recognizing reduced use should therefore sharpen the treatment plan, not replace it.

The psychiatrist still needs to ask what care was delivered, what the patient actually received, what harms remain, and what intervention is indicated next. Improvement during treatment may reflect behavioral care, contingency management, medication exposure, changes in environment, growing motivation, regression toward the mean, or several factors operating together.

The chart should distinguish the observed trajectory from the explanation assigned to it.

Toxicology can identify exposure that self-report misses and can help clarify a trajectory. It should not be ignored. But a positive result does not answer every question a psychiatrist needs to ask.

A more useful follow-up documents at least:

This creates a longitudinal record. It also makes the plan more precise. A patient who reduced use but developed chest pain needs a different response from a patient who reduced use, returned to work, and remains medically stable. A patient who improved while barely taking a medication offers different information from a patient who adhered, tolerated it, and received concurrent contingency management.

Five questions can improve the assessment:

The wording in the chart can then become more accurate:

That is not therapeutic optimism disguised as measurement. It is measurement replacing a verdict.

ASAM's clinical consideration on nonabstinent patients states that current substance use should not by itself block access to treatment. Continued use should generally prompt collaborative reassessment rather than administrative discharge. There are legitimate exceptions when a program cannot maintain safety or when a patient needs a different level of care.

Keeping a patient in treatment does not mean approving continued use. It means treating recurrence, nonadherence, and changing motivation as clinical information. The response may include intensifying care, changing the plan, addressing barriers, adding contingency management, treating co-occurring illness, or arranging a warm transition.

The false choice is between demanding immediate abstinence and declaring reduced use sufficient. Good care can hold a safer long-term goal while recognizing meaningful movement toward it.

Reduced stimulant use is not automatically treatment failure. It is also not automatically treatment success, adequate safety, or evidence that a medication worked.

It is a signal to measure carefully.

For psychiatrists, the practical task is to preserve the difference among progress, causation, and safety. Record the trajectory. Assess the remaining harms. Identify the treatment that was actually delivered. Keep the patient engaged when care can be provided safely. Then decide what the next target should be.

1. Amin-Esmaeili M, et al. Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials. Addiction. 2024;119(5):833-843. Correction.

2. ASAM/AAAP. The Clinical Practice Guideline on the Management of Stimulant Use Disorder. 2024.

3. American Society of Addiction Medicine. Engagement and Retention of Nonabstinent Patients in Substance Use Treatment. 2024.

Educational Disclaimer: The Psychiatric Record provides general educational information for psychiatric and mental-health professionals. Content does not constitute medical, legal, regulatory, compliance, billing, or other professional advice; does not establish a standard of care; and is not a substitute for independent professional judgment. Appropriate assessment and treatment depend on the patient, setting, available interventions, evidence, and current authoritative guidance. This article does not recommend starting, continuing, stopping, or changing any medication or treatment plan for any individual. Recognizing reduced use is not an endorsement of ongoing stimulant use and is not a determination of safety. The patient described is a fictional composite; no individual is depicted.